Cencora (COR) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
9 Mar, 2026Opening remarks and agenda
Meeting called to order by the CEO, who also served as chair, with the secretary reviewing rules and agenda.
Business portion conducted first, followed by a business presentation and Q&A session.
Voting included election of directors, executive compensation advisory vote, and auditor ratification.
Board and executive committee updates
Eleven director nominees were presented for election, with brief biographies available in the proxy statement.
All nominees were reelected to serve for a one-year term.
Shareholder proposals
No additional business or shareholder proposals were brought forward in accordance with bylaws.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Cencora
- Q3 FY2026 saw 5.1% revenue growth, higher EPS, and raised guidance, with $1B in share buybacks.COR
Q3 2026 - Raised guidance and specialty investments drive strong growth and long-term confidence.COR
Barclays 28th Annual Global Healthcare Conference - Key votes include board elections, executive pay, and auditor ratification at the 2025 annual meeting.COR
Proxy Filing - Guidance reaffirmed, growth to accelerate, $1B buybacks planned, and AI-driven efficiencies prioritized.COR
Bank of America Global Healthcare Conference 2026 - Q2 FY2026 delivered 3.8% revenue growth, higher EPS, and a $1.1B OneOncology gain.COR
Q2 2026 - Expanded MSO ownership and robust specialty growth drive higher guidance and strategic focus.COR
Leerink Global Healthcare Conference 2026 - Q1 FY2026 revenue up 5.5% to $85.9B; adjusted EPS rose 9.4% to $4.08.COR
Q1 2026 - Adjusted EPS and revenue climbed double digits, with 2025 growth and RCA deal ahead.COR
Q4 2024 - Specialty growth, biosimilars, and disciplined capital deployment drive strong performance.COR
43rd Annual J.P. Morgan Healthcare Conference